455280-00-9

Basic information

• Product Name: 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE
• Synonyms: 5-BROMO-1,2-BENZISOXAZOL-3-YLAMINE;5-broMo-1,2-benzoxazol-3-aMine;3-AMino-5-broMobenzo[d]isoxazole
• CAS NO: 455280-00-9
• Molecular Formula: C₇H₅BrN₂O
• Molecular Weight: 213.04
• Mol File: 455280-00-9.mol

Chemical Properties

• Boiling Point: 371.1°C at 760 mmHg
• Flash Point: 178.2°C
• Appearance: /
• Density: 1.804g/cm³
• Vapor Pressure: 1.06E-05mmHg at 25°C
• Refractive Index: 1.715
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE(455280-00-9)
• EPA Substance Registry System: 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE(455280-00-9)

Safety Data

• Hazardous Substances Data: 455280-00-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE is used as a chemical building block for the synthesis of new compounds with potential therapeutic applications. Its unique structure and properties allow researchers to explore its use in creating innovative drugs for various medical conditions.
Used in Agrochemical Research and Development:
In the agrochemical industry, 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE is utilized as a starting material for the development of new agrochemicals. Its potential in this field is attributed to its ability to be incorporated into compounds that can address agricultural challenges, such as pest control and crop protection.
Used in Medicinal Chemistry:
5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE is employed as a key component in the design and synthesis of novel compounds with potential medicinal properties. Its versatility in chemical reactions enables the creation of diverse molecules that can target specific biological pathways or receptors, contributing to the advancement of drug discovery.
Used in Chemical Synthesis:
As a chemical intermediate, 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE is used in various chemical synthesis processes. Its reactivity and functional groups make it suitable for the preparation of a wide range of organic compounds, including those with potential applications in materials science, dyes, and other specialty chemicals.
Ongoing research and development in the field of pharmaceutical and agrochemical sciences continue to explore the potential of 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE as a versatile and important chemical building block, paving the way for new discoveries and innovations in these industries.

InChI:InChI=1/C7H5BrN2O/c8-4-1-2-6-5(3-4)7(9)10-11-6/h1-3H,(H2,9,10)

Upstream product

• 546-88-3 acetylhydroxamic acid 
• 179897-89-3 5-Bromo-2-fluoro-benzonitrile 

Downstream Products

• 1432914-24-3 di-tert-butyl [5-(3-bromo-5-chloro-2-hydroxyphenyl)-1,2-benzoxazol-3-yl]imidodicarbonate 
• 1432912-65-6 di-tert-butyl [5-(5-chloro-2-hydroxyphenyl)-1,2-benzoxazol-3-yl]imidodicarbonate 
• 1432912-84-9 di-tert-butyl (5-{4-[(2,4-dimethoxybenzyl)(1,2,4-thiadiazol-5-yl)sulfamoyl]-2,5-difluorophenoxy}-1,2-benzoxazol-3-yl)imidodicarbonate 
• 1432913-44-4 4-(2-(3-aminobenzo[d]isoxazol-5-yl)-4-chlorophenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432913-94-4 tert-butyl (5-(5-chloro-2-hydroxyphenyl)benzo[d]isoxazol-3-yl)carbamate 
• 1432913-93-3 tert-butyl (5-(5-chloro-2-(4-(N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)sulfamoyl)-2,5-difluorophenoxy)phenyl)benzo[d]isoxazol-3-yl)carbamate 
• 1432913-96-6 tert-butyl (5-(5-chloro-2-(4-(N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)sulfamoyl)-2,5-difluorophenoxy)-phenyl)-benzo[d]isoxazol-3-yl)(methyl)carbamate 
• 1432913-95-5 4-(4-chloro-2-(3-(methylamino)benzo[d]isoxazol-5-yl)phenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432913-68-2 4-(2-(3-aminobenzo[d]isoxazol-5-yl)phenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432914-11-8 di-tert-butyl [5-(5-fluoro-2-hydroxyphenyl)-1,2-benzoxazol-3-yl]imidodicarbonate 
• 1432914-10-7 4-(2-(3-aminobenzo[d]isoxazol-5-yl)-4-fluorophenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432913-72-8 4-(3-(3-aminobenzo[d]isoxazol-5-yl)-2-oxopyridin-1(2H)-yl)-N-(2,4-dimethoxybenzyl)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 

Relevant articles and documents

BENZENE FUSED HETEROCYCLIC COMPOUND AND USE THEREOF

The present disclosure provides a benzene fused heterocyclic compound of Formula (I): wherein (A) is a single or double bond; n is 0 or 1; X is -CH2-, O, NR1, or S; A is -C(Ra1)(Ra2)(Ra3) or -N(R

Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models

We report on a novel series of aryl sulfonamides that act as nanomolar potent, isoform-selective inhibitors of the human sodium channel hNaV1.7. The optimization of these inhibitors is described. We aimed to improve potency against hNaV1.7 while minimizing off-target safety concerns and generated compound 3. This agent displayed significant analgesic effects in rodent models of acute and inflammatory pain and demonstrated that binding to the voltage sensor domain 4 site of NaV1.7 leads to an analgesic effect in vivo. Our findings corroborate the importance of hNaV1.7 as a drug target for the treatment of pain.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.

Discovery of dual death-associated protein related apoptosis inducing protein kinase 1 and 2 inhibitors by a scaffold hopping approach

DRAK2 emerged as a promising drug target for the treatment of autoimmune diseases and to prevent graft rejection after organ transplantation. Screening of a compound library in a DRAK2 binding assay led to the identification of an isothiazolo[5,4-b]pyridine derivative as a novel ligand for DRAK2, displaying a Kdvalue of 1.6 μM. Subsequent medicinal chemistry work led to the discovery of a thieno[2,3-b]pyridine derivative with strong DRAK2 binding affinity (Kd= 9 nM). Moreover, this compound also behaves as a functional inhibitor of DRAK2 enzymatic activity, displaying an IC50value of 0.82 μM, although lacking selectivity, when tested against DRAK1. This paper describes for the first time functionally active dual DRAK1 and DRAK2 inhibitors that can be used as starting point for the synthesis of chemical tool compounds to study DRAK1 and DRAK2 biology, or they can be considered as hit compounds for hit-to-lead optimization campaigns in drug discovery programs.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

The substituted benzo(d)isoxazol-3-yl-amine compounds of general formula (I) are suitable for treating pains and have an excellent affinity to vanilloid receptor subtype 1 (VR1/TRPV1 receptor) and are therefore especially useful in the prophylaxis and/or